[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648194":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":20,"enrollmentInfo":39,"targetDuration":20,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":20,"overallStatus":48,"whyStopped":20,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":20},{"fullName":5,"class":6},"University Hospital, Limoges","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with de novo diagnosis of GCA","EXPERIMENTAL","Blood samples for CRP determination",[13],"Diagnostic Test: Blood tests to measure CRP",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Blood tests to measure CRP","Blood tests to measure CRP levels",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Kim LY, Professor","CONTACT","05 55 05 05 05","Kim.Ly@chu-limoges.fr",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100648194","kinetics-of-c-reactive-protein-in-giant-cell-arteritis-following-glucocorticoid-initiation-a-pilot-study-gideon-100648194",false,"NCT07720804","Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)","Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study","GIDEON","Inclusion Criteria:\n\n* Adult patients aged 18 or older hospitalized in the internal medicine department with a new diagnosis of ACG\n* Personne affiliée ou bénéficiaire d'un régime de sécurité sociale\n* Free and informed consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Patients scheduled to be placed on a sparing regimen during hospitalization\n* Patients with renal insufficiency (eGFR ≤ 60 mL\u002Fmin\u002F1.73 m²)\n* Patients with a history of corticosteroid-treated pseudopolyarthritis\n* Patients with ACG and visual impairment (severity criterion)\n* Patients on immunosuppressants or biologic therapy\n* HIV infection or progressive malignancy\n* Known poor treatment adherence\n* Dementia\n* Pregnant or breastfeeding women\n* Patients under legal guardianship","ALL","18 Years",{"count":40,"type":41},40,"ESTIMATED","INTERVENTIONAL",[44],"NA","We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and\u002For relapses.\n\nEarly assessment of the rate of CRP normalization would enable us to adapt the therapeutic strategy in order to avoid complications and\u002For relapses.",[47],"Giant Cell Arteritis (GCA)","NOT_YET_RECRUITING","2026-07-17",{"date":51,"type":52},"2026-07-22","ACTUAL",{"date":54,"type":41},"2026-06-22",{"date":56,"type":41},"2030-06-22",{"name":5,"class":6}]